Cited by 889Cancer therapeutics and mechanismsBioactive Compounds and Antitumor AgentsMetal complexes synthesis and properties

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II

Open access

Tewey, K M, Chen, G L, Nelson, E M, Liu, L F·1984·Journal of Biological Chemistry

DOI 10.1016/s0021-9258(17)47282-6

Open this paper in CoChat — free account

Abstract

Many intercalative antitumor drugs have been shown to induce reversible protein-linked DNA breaks in cultured mammalian cells. Using purified mammalian DNA topoisomerase II, we have demonstrated that the antitumor drugs ellipticine and 2-methyl-9-hydroxyellipticine (2-Me-9-OH-E+) can produce reversible protein-linked DNA breaks in vitro. 2-Me-9-OH-E+ which is more cytotoxic toward L1210 cells and more active against experimental tumors than ellipticine is also more effective in stimulating DNA cleavage in vitro. Similar to the effect of 4'-(9-acridinylamino)-methanesulfon-m-anisidide (m-AMSA) on topoisomerase II in vitro, the mechanism of DNA breakage induced by ellipticines is most likely due to the drug stabilization of a cleavable complex formed between topoisomerase II and DNA. Protein denaturant treatment of the cleavable complex results in DNA breakage and covalent linking of one topoisomerase II subunit to each 5'-end of the cleaved DNA. Cleavage sites on pBR322 DNA produced by ellipticine or 2-Me-9-OH-E+ treatment mapped at the same positions. However, many of these cleavage sites are distinctly different from those produced by the antitumor drug m-AMSA which also targets at topoisomerase II. Our results thus suggest that although mammalian DNA topoisomerase II may be a common target of these antitumor drugs, drug-DNA-topoisomerase interactions for different antitumor drugs may be different.

Integrity signals

Registry

Crossref · 10.1016/s0021-9258(17)47282-6

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

DNA Topoisomerases
Gellert, M. F. (1981) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.50.070181.004311 · Cited by 990
DNA Gyrase and the Supercoiling of DNA
Cozzarelli, N. R. (1980) · Science · doi:10.1126/science.6243420 · Cited by 720
DNA Modification and Cancer
Waring, M. J. (1981) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.50.070181.001111 · Cited by 690
The Anticancer Agent Adriamycin Can Be Actively Cytotoxic Without Entering Cells
Triton, T. R., & Yee, G. K. (1982) · Science · doi:10.1126/science.7089561 · Cited by 573
Mechanism of antitumor drug action: poisoning of mammalian DNA topoisomerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide.
Nelson, E. M., Tewey, K. M., & Liu, L. F. (1984) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.81.5.1361 · Cited by 561
Self-citation
Cleavage of DNA by mammalian DNA topoisomerase II.
Liu, L. F., Rowe, T. C., Yang, L., Tewey, K. M., & Chen, G. L. (1983) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)43815-4 · Cited by 534
Self-citation
Type II DNA topoisomerases: enzymes that can unknot a topologically knotted DNA molecule via a reversible double-strand break.
Liu, L. F., Liu, C.-C., & Alberts, B. (1980) · Cell · doi:10.1016/s0092-8674(80)80046-8 · Cited by 486
Self-citation
Protein-associated deoxyribonucleic acid strand breaks in L1210 cells treated with the deoxyribonucleic acid intercalating agents 4'-(9-acridinylamino)methanesulfon-m-anisidide and adriamycin
Zwelling, L. A., Michaels, S., Erickson, L. C., Ungerleider, R. S., Nichols, M., & Kohn, K. W. (1981) · Biochemistry · doi:10.1021/bi00526a006 · Cited by 374
A homogeneous type II DNA topoisomerase from HeLa cell nuclei.
Miller, K. G., Liu, L. F., & Englund, P. T. (1981) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52552-2 · Cited by 359
Self-citation
Terminal stages of SV40 DNA replication proceed via multiply intertwined catenated dimers
Sundin, O. H., & Varshavsky, A. J. (1980) · Cell · doi:10.1016/0092-8674(80)90118-x · Cited by 354

Show all 39 references

Research works printed but not linked: 3

Zwelling, 1982, Cancer Res., 42, 2687
Burr-Furlong, 1978, Cancer Res., 38, 1329
Pommier, 1982, Biochem. Biophys. Res. Commun., 77, 1150

Sorted by citations

Items 101–200 of 889

Combined modalities of resistance in etoposide-resistant human KB cell lines.
Ferguson, P. J., Fisher, M. H., Stephenson, J., Li, D. H., Zhou, B., & Cheng, Y.-C. (1988) · PubMed · Cited by 147
Induction of topoisomerase II-mediated DNA cleavage by the plant naphthoquinones plumbagin and shikonin
Fujii, N., Yamashita, Y., Arima, Y., Nagashima, M., & Nakano, H. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.12.2589 · Cited by 146
Induction of mammalian DNA topoisomerase I mediated DNA cleavage by antitumor indolocarbazole derivatives
Yamashita, Y., Fujii, N., Murakata, C., Ashizawa, T., Okabe, M., & Nakano, H. (1992) · Biochemistry · doi:10.1021/bi00163a015 · Cited by 145
Differential and Common DNA Repair Pathways for Topoisomerase I- and II-Targeted Drugs in a Genetic DT40 Repair Cell Screen Panel
Maede, Y., Shimizu, H., Fukushima, T., Kogame, T., Nakamura, T., Miki, T., Takeda, S., Pommier, Y. G., & Murai, J. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0551 · Cited by 142
“Another notable finding is that doxorubicin, which unambiguously generates Top2cc (36, 37), did not sensitize TDP2-deficient cells, as well as etoposide and ICRF-193, and showed relatively low correlation with etoposide and ICRF-193 (Fig.”
Background
Topoisomerase Inhibitors Can Selectively Interfere with Different Stages of Simian Virus 40 DNA Replication
Snapka, R. M. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.12.4221-4227.1986 · Cited by 141
Isolation of intercalator-dependent protein-linked DNA strand cleavage activity from cell nuclei and identification as topoisomerase II
Minford, J., Pommier, Y. G., Filipski, J., Kohn, K. W., Kerrigan, D., Mattern, M. R., Michaels, S., Schwartz, R. E., & Zwelling, L. A. (1986) · Biochemistry · doi:10.1021/bi00349a002 · Cited by 141
Multidrug resistance in mitoxantrone-selected HL-60 leukemia cells in the absence of P-glycoprotein overexpression.
Harker, W. G., Slade, D., Dalton, W. S., Meltzer, P. S., & Trent, J. M. (1989) · PubMed · Cited by 140
Nanoparticle delivery of anticancer drugs overcomes multidrug resistance in breast cancer
Yuan, Y., Cai, T., Xia, X., Zhang, R., Chiba, P., & Cai, Y. (2016) · Drug Delivery · doi:10.1080/10717544.2016.1178825 · Cited by 141
“TopoisomeraseII (TopoII) is an ATP-dependent enzyme that catalyzes the topological passing of two double-stranded DNA segments, and creates an intermediate DNA-enzyme complex referred to as the ‘‘cleavable complex’’ (Miller et al., 1981; Tewey et al., 1984).”
Background
Topoisomerase II Binds to Ellipticine in the Absence or Presence of DNA.
Froelich-Ammon, S. J., Patchan, M. W., Osheroff, N., & Thompson, R. B. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.25.14998 · Cited by 137
Relationship between the intracellular effects of camptothecin and the inhibition of DNA topoisomerase I in cultured L1210 cells.
Mattern, M. R., Mong, S. M., BARTUS, H. F., Mirabelli, C. K., Crooke, S. T., & Johnson, R. K. (1987) · PubMed · Cited by 138
DNA topoisomerase II: A primer on the enzyme and its unique role as a multidrug target in cancer chemotherapy
Glisson, B. S., & Ross, W. E. (1987) · Pharmacology & Therapeutics · doi:10.1016/0163-7258(87)90054-4 · Cited by 137
Localization of Specific Topoisomerase I Interactions within the Transcribed Region of Active Heat Shock Genes by Using the Inhibitor Camptothecin
Gilmour, D. S., & Elgin, S. C. R. (1987) · Molecular and Cellular Biology · doi:10.1128/mcb.7.1.141 · Cited by 136
Peptide sequencing and site-directed mutagenesis identify tyrosine-727 as the active site tyrosine of Saccharomyces cerevisiae DNA topoisomerase I.
Lynn, R. M., Bjornsti, M., Caron, P. R., & Wang, J. C. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.10.3559 · Cited by 135
In vivo mapping of DNA topoisomerase II-specific cleavage sites on SV40 chromatin
Liu, Y., Rowe, T. C., Nelson, E. M., & Liu, L. F. (1985) · Cell · doi:10.1016/0092-8674(85)90067-4 · Cited by 135
Self-citation
Suramin is an inhibitor of DNA topoisomerase II in vitro and in Chinese hamster fibrosarcoma cells.
Bojanowski, K., Lelièvre, S. A., Markovits, J., Couprie, J., Jacquemin‐Sablon, A., & Larsen, A. K. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.7.3025 · Cited by 132
ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children
Felix, C., Hosler, M. R., Winick, N., Masterson, M., Wilson, A., & Lange, B. (1995) · Blood · doi:10.1182/blood.v85.11.3250.bloodjournal85113250 · Cited by 129
Activation of internucleosomal DNA cleavage in human CEM lymphocytes by glucocorticoid and novobiocin. Evidence for a non-Ca2(+)-requiring mechanism(s).
Alnemri, E. S., & Litwack, G. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44906-4 · Cited by 132
Biochemical mechanisms of chromosomal translocations resulting from DNA double-strand breaks
Povirk, L. F. (2006) · DNA repair · doi:10.1016/j.dnarep.2006.05.016 · Cited by 134
Topoisomerase II inhibitors
Hande, K. R. (2006) · Update on Cancer Therapeutics · doi:10.1016/j.uct.2006.04.001 · Cited by 131
A Novel High-Through-Put Assay for Screening of Pro-Apoptotic Drugs
Hägg, M., Bivén, K., Ueno, T., Rydlander, L., Björklund, P., Wiman, K. G., Shoshan, M. C., & Linder, S. T. (2002) · Investigational New Drugs · doi:10.1023/a:1016249728664 · Cited by 128
Potentiation of doxorubicin cytotoxicity by buthionine sulfoximine in multidrug-resistant human breast tumor cells.
Dusre, L., Mimnaugh, E. G., Myers, C. E., & Sinha, B. K. (1989) · PubMed · Cited by 127
Effects of the DNA intercalators 4'-(9-acridinylamino)methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase II mediated DNA strand cleavage and strand passage
Pommier, Y. G., Minford, J., Schwartz, R. E., Zwelling, L. A., & Kohn, K. W. (1985) · Biochemistry · doi:10.1021/bi00344a015 · Cited by 127
Double-stranded DNA cleavage/religation reaction of eukaryotic topoisomerase II: evidence for a nicked DNA intermediate
Zechiedrich, L., Christiansen, K., Andersen, A. H., Westergaard, O., & Osheroff, N. (1989) · Biochemistry · doi:10.1021/bi00441a014 · Cited by 126
Tandem Regions of Yeast DNA Topoisomerase II Share Homology with Different Subunits of Bacterial Gyrase
Lynn, R., Giaever, G. N., Swanberg, S. L., & Wang, J. C. (1986) · Science · doi:10.1126/science.3014661 · Cited by 126
DNA topoisomerase I and II as targets for rational design of new anticancer drugs
Cummings, J., & Smyth, J. F. (1993) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a058584 · Cited by 125
“Since the discovery in the mid 1980s that several of the most effective anticancer drugs such as doxorubicin (DOX), etoposide (VP-16) and camptothecin (CPT) interrupt the normal catalytic cycle of topoisomerase I (CPT) and H (DOX, VP-16) (topo I and H) [1-3], these key enzymes have become important new targets for rat…”
Background
High positive supercoiling in vitro catalyzed by an ATP and polyethylene glycol‐stimulated topoisomerase from Sulfolobus acidocaldarius.
Forterre, P., Mirambeau, G., Jaxel, C., Nadal, M., & Duguet, M. (1985) · The EMBO Journal · doi:10.1002/j.1460-2075.1985.tb03902.x · Cited by 124
Camptothecin-resistant mutants of Chinese hamster ovary cells containing a resistant form of topoisomerase I.
Gupta, R. S., Gupta, R., Eng, B., Lock, R. B., Ross, W. E., Hertzberg, R., Caranfa, M. J., & Johnson, R. K. (1988) · PubMed · Cited by 124
Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells
Catalano, M. G., Fortunati, N., Pugliese, M., Poli, R., Bosco, O., Mastrocola, R., Aragno, M., & Boccuzzi, G. (2006) · Journal of Endocrinology · doi:10.1677/joe.1.06970 · Cited by 121
“…the hyperacetylation of histones and subsequent relaxation of chromatin, may enhance the cytotoxicity of drugs targeting DNA (Kim et al. 2003, Marchion et al. 2004, 2005), such as doxorubicin, whose anti-tumor activities involve binding to DNA and inhibiting topoisomerase II (Tewey et al. 1984).”
Background
Mode of action of topoisomerase II-targeting agents at a specific DNA sequence
Sørensen, B. S., Sinding, J., Andersen, A. H., Alsner, J., Jensen, P. B., & Westergaard, O. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90863-f · Cited by 122
CtIP and MRN promote non-homologous end-joining of etoposide-induced DNA double-strand breaks in G1
Quennet, V., Beucher, A., Barton, O., Takeda, S., & Löbrich, M. (2010) · Nucleic Acids Research · doi:10.1093/nar/gkq1175 · Cited by 125
The antileukemic alkaloid fagaronine is an inhibitor of DNA topoisomerases I and II
Larsen, A. K., Grondard, L., Couprie, J., Desoize, B., Comoë, L., Jc, J., & Riou, J. (1993) · Biochemical Pharmacology · doi:10.1016/0006-2952(93)90105-6 · Cited by 119
Etoposide
Henwood, J. M., & Brogden, R. N. (1990) · Drugs · doi:10.2165/00003495-199039030-00008 · Cited by 119
Assembly of spaced chromatin involvement of ATP and DNA topoisomerase activity.
Almouzni, G., & Méchali, M. (1988) · The EMBO Journal · doi:10.1002/j.1460-2075.1988.tb03334.x · Cited by 115
Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus
Yamashita, Y., Kawada, S., Fujii, N., & Nakano, H. (1991) · Biochemistry · doi:10.1021/bi00238a005 · Cited by 119
Inhibition of type II topoisomerase by fostriecin
Boritzki, T. J., Wolfard, T. S., Besserer, J. A., Jackson, R., & Fry, D. W. (1988) · Biochemical Pharmacology · doi:10.1016/0006-2952(88)90096-2 · Cited by 118
P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy.
van der Zee, A. G. J., Hollema, H., de Jong, S., Boonstra, H., Gouw, A., Willemse, P. H. B., Zijlstra, J. G., & de Vries, E. G. E. (1991) · PubMed · Cited by 118
Selective elimination of mutant mitochondrial genomes as therapeutic strategy for the treatment of NARP and MILS syndromes
ALEXEYEV, M. F., Venediktova, N. I., Pastukh, V. M., Shokolenko, I. N., Bonilla, G., & Wilson, G. L. (2008) · Gene Therapy · doi:10.1038/gt.2008.11 · Cited by 117
Hybrid Lipid-Capped Mesoporous Silica for Stimuli-Responsive Drug Release and Overcoming Multidrug Resistance
Han, N., Zhao, Q., Wan, L., Wang, Y., Gao, Y., Wang, P., Wang, Z., Zhang, J., Jiang, T., & Wang, S. (2015) · ACS Applied Materials & Interfaces · doi:10.1021/am5082793 · Cited by 121
DNA sequence selectivity of topoisomerases and topoisomerase poisons
Capranico, G., & Binaschi, M. (1998) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/s0167-4781(98)00135-3 · Cited by 116
Synthesis, anticancer activity and QSAR study of 1,4-naphthoquinone derivatives
Prachayasittikul, V., Pingaew, R., Worachartcheewan, A., Nantasenamat, C., Prachayasittikul, S., Ruchirawat, S., & Prachayasittikul, V. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.07.024 · Cited by 116
DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives
Monnot, M., Mauffret, O., Simon, V., Lescot, E., Psaume, B., Saucier, J.-M., Charra, M., Belehradek, J., & Fermandjian, S. (1991) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)52368-1 · Cited by 113
Topoisomerase Assays
Nitiss, J. L., Soans, E., Rogojina, A. T., Seth, A., & Mishina, M. (2012) · Current Protocols in Pharmacology · doi:10.1002/0471141755.ph0303s57 · Cited by 112
“The most likely explanation for this pattern of responses is that high levels of compound intercalated in DNA completely block cleavage (Tewey et al., 1984).”
Background
Pharmacokinetics and Metabolism of Mitoxantrone
Ehninger, G., Schuler, U. S., Proksch, B., Zeller, K., & Blanz, J. (1990) · Clinical Pharmacokinetics · doi:10.2165/00003088-199018050-00003 · Cited by 110
BRCA1- and BRCA2-Deficient Cells Are Sensitive to Etoposide-Induced DNA Double-Strand Breaks via Topoisomerase II
Treszezamsky, A. D., Kachnic, L. A., Feng, Z., Zhang, J., Tokadjian, C., & Powell, S. N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0601 · Cited by 113
Topoisomerase II-mediated DNA breaks and cytotoxicity in relation to cell proliferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells.
Markovits, J., Pommier, Y. G., Kerrigan, D., Covey, J. M., Tilchen, E. J., & Kohn, K. W. (1987) · PubMed · Cited by 109
Developmental Regulation of Topoisomerase II Sites and DNase I-Hypersensitive Sites in the Chicken β-Globin Locus
Reitman, M. L., & Felsenfeld, G. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.6.2774-2786.1990 · Cited by 108
Camptothecin, teniposide, or 4'-(9-acridinylamino)-3-methanesulfon-m-anisidide, but not mitoxantrone or doxorubicin, induces degradation of nuclear DNA in the S phase of HL-60 cells.
Bino, G. D., & Darżynkiewicz, Z. (1991) · PubMed · Cited by 108
Human induced pluripotent stem cells as a platform for personalized and precision cardiovascular medicine
Matsa, E., Ahrens, J. H., & Wu, J. C. (2016) · Physiological Reviews · doi:10.1152/physrev.00036.2015 · Cited by 105
Nonclassical Biological Activities of Quinolone Derivatives
Daneshtalab, M., & Ahmed, A. A. (2011) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/j3302n · Cited by 109
Involvement of the AML1 gene in the t(3;21) in therapy-related leukemia and in chronic myeloid leukemia in blast crisis.
Nucifora, G., Birn, D. J., Espinosa, R., Erickson, P., Beau, M. M. L., Roulston, D., McKeithan, T. W., Drabkin, H. A., & Rowley, J. D. (1993) · PubMed · Cited by 106
A New Antitumor Agent Amrubicin Induces Cell Growth Inhibition by Stabilizing Topoisomerase II‐DNA Complex
Hanada, M., Mizuno, S., Fukushima, A., Saito, Y. M., Noguchi, T., & Yamaoka, T. (1998) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1998.tb00519.x · Cited by 106
Some fused heterocyclic compounds as eukaryotic topoisomerase II inhibitors
Pinar, A., Yurdakul, P., Yıldız, İ., Temiz‐Arpacı, Ö., Açan, N. L., Aki, E., & Yalçın, İ. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.03.093 · Cited by 105
Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4′-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage
Jensen, P. B. (1991) · Lung Cancer · doi:10.1016/0169-5002(91)90222-r · Cited by 105
Delayed cytotoxicity and cleavage of mitochondrial DNA in ciprofloxacin-treated mammalian cells.
Lawrence, J. W., Claire, D., Weissig, V., & Rowe, T. C. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09546-x · Cited by 104
Induction of Topoisomerase II-Mediated DNA Cleavage by a Protoberberine Alkaloid, Berberrubine
Kim, S. A., Kwon, Y. V., Kim, J. H., Muller, M. T., & Chung, I. K. (1998) · Biochemistry · doi:10.1021/bi9810961 · Cited by 104
Method To Detect Only Live Bacteria during PCR Amplification
Soejima, T., Iida, K., Qin, T., Taniai, H., Seki, M., & Yoshida, S. (2008) · Journal of Clinical Microbiology · doi:10.1128/jcm.02171-07 · Cited by 103
Inhibition of epipodophyllotoxin cytotoxicity by interference with topoisomerase-mediated DNA cleavage
Rowe, T. C., Kupfer, G. M., & Ross, W. E. (1985) · Biochemical Pharmacology · doi:10.1016/0006-2952(85)90530-1 · Cited by 103
Doxorubicin pharmacokinetics: Macromolecule binding, metabolism, and excretion in the context of a physiologic model
Gustafson, D. L., Rastatter, J. C., Colombo, T., & Long, M. E. (2002) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.10161 · Cited by 102
Mechanisms of resistance to etoposide and teniposide in acquired resistant human colon and lung carcinoma cell lines.
Long, B. H., Wang, L., Lorico, A., Wang, R. C., Brattain, M. G., & Casazza, A. (1991) · PubMed · Cited by 102
Chromosome band 11q23 translocation breakpoints are DNA topoisomerase II cleavage sites.
Felix, C. A., Lange, B. J., Hosler, M. R., Fertala, J., & Bjornsti, M. (1995) · PubMed · Cited by 101
Cloning and characterization of the 5'-flanking region of the human topoisomerase II alpha gene.
Hochhauser, D., Stanway, C. A., Harris, A. L., & Hickson, I. D. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)37054-1 · Cited by 101
Cell cycle control of higher-order chromatin assembly around naked DNA in vitro.
Hirano, T., & Mitchison, T. J. (1991) · The Journal of Cell Biology · doi:10.1083/jcb.115.6.1479 · Cited by 101
Topoisomerase II can unlink replicating DNA by precatenane removal
Lucas, I., Germe, T. R., Chevrier‐Miller, M., & Hyrien, O. (2001) · The EMBO Journal · doi:10.1093/emboj/20.22.6509 · Cited by 100
A nucleotide resolution map of Top2-linked DNA breaks in the yeast and human genome
Gittens, W. H., Johnson, D., Allison, R. M., Cooper, T. J., Thomas, H., & Neale, M. J. (2019) · Nature Communications · doi:10.1038/s41467-019-12802-5 · Cited by 99
Irreversible trapping of the DNA-topoisomerase I covalent complex. Affinity labeling of the camptothecin binding site.
Hertzberg, R., Busby, R. W., Caranfa, M. J., Holden, K. G., Johnson, R. K., Hecht, S. M., & Kingsbury, W. D. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)30656-7 · Cited by 99
DNA Topoisomerases as Targets for the Anticancer Drug TAS-103: DNA Interactions and Topoisomerase Catalytic Inhibition
Fortune, J. M., Velea, L., Graves, D. E., Utsugi, T., Yamada, Y., & Osheroff, N. (1999) · Biochemistry · doi:10.1021/bi991792g · Cited by 96
Anthracyclines in haematology: preclinical studies, toxicity and delivery systems
Richardson, D. S., & Johnson, S. A. (1997) · Blood Reviews · doi:10.1016/s0268-960x(97)90020-5 · Cited by 96
Anticancer drug discovery in the future: an evolutionary perspective
Ma, X., & Wang, Z. (2009) · Drug Discovery Today · doi:10.1016/j.drudis.2009.09.006 · Cited by 96
Novel partitioning of DNA cleavage sites for Drosophila topoisomerase II
Udvardy, A., Schedl, P. D., Sander, M., & Hsieh, T. (1985) · Cell · doi:10.1016/0092-8674(85)90353-8 · Cited by 96
Sequence specificity of DNA topoisomerase I in the presence and absence of camptothecin.
Thomsen, B., Mollerup, S., Bonven, B. J., Frank, R. W., Blöcker, H., NIELSEN, O. F., & Westergaard, O. (1987) · The EMBO Journal · doi:10.1002/j.1460-2075.1987.tb02436.x · Cited by 94
In vivo localization of DNA topoisomerase II cleavage sites on Drosophila heat shock chromatin.
Rowe, T. C., Wang, J. C., & Liu, L. F. (1986) · Molecular and Cellular Biology · doi:10.1128/mcb.6.4.985 · Cited by 94
Self-citation
Specificity and Functional Significance of DNA Interaction with the Nuclear Matrix: New Approaches to Clarify the Old Questions
Razin, S. V., Gromova, I., & Iarovaia, O. V. (1996) · International review of cytology · doi:10.1016/s0074-7696(08)62623-6 · Cited by 94
Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II
Lee, M.-S., Wang, J. C., & Beran, M. (1992) · Journal of Molecular Biology · doi:10.1016/0022-2836(92)90245-f · Cited by 93
Use of in vitro topoisomerase II assays for studying quinolone antibacterial agents
Barrett, J. F., Gootz, T. D., McGuirk, P. R., Farrell, C. A., & Sokolowski, S. A. (1989) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.33.10.1697 · Cited by 92
Mitotic repression of transcription in vitro.
Hartl, P. M., Gottesfeld, J. M., & Forbes, D. J. (1993) · The Journal of Cell Biology · doi:10.1083/jcb.120.3.613 · Cited by 92
Topoisomerase inhibitors as anticancer agents: a patent update
Khadka, D. B., & Cho, W. (2013) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2013.790958 · Cited by 91
“1984 [113] Acridine (m-AMSA) II 1984 [114] Ellipticine II 1984 [115] Epipodophyllotoxin (etoposide, teniposide) II”
Background
Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4'-(9-acridinylamino)methanesulfon-m-anisidide
Robinson, M. J., & Osheroff, N. (1990) · Biochemistry · doi:10.1021/bi00462a012 · Cited by 91
Single-strand DNA cleavages by eukaryotic topoisomerase II
Muller, M. T., Spitzner, J. R., DiDonato, J. A., Mehta, V. B., Tsutsui, K., & Tsutsui, K. (1988) · Biochemistry · doi:10.1021/bi00422a012 · Cited by 91
Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways
Nyåkern, M., Cappellini, A., Mantovani, I., & Martelli, A. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0076 · Cited by 90
Swiveling and Decatenation of Replicating Simian Virus 40 Genomes in Vivo
Snapka, R. M., Powelson, M. A., & Strayer, J. M. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.2.515 · Cited by 90
Targeting the DNA damage response for cancer therapy
Powell, S. N., & Bindra, R. S. (2009) · DNA repair · doi:10.1016/j.dnarep.2009.04.011 · Cited by 86
Tyrosyl-DNA phosphodiesterase I resolves both naturally and chemically induced DNA adducts and its potential as a therapeutic target
Comeaux, E. Q., & van Waardenburg, R. C. A. M. (2014) · Drug Metabolism Reviews · doi:10.3109/03602532.2014.971957 · Cited by 91
Induction of apoptosis by plumbagin through reactive oxygen species-mediated inhibition of topoisomerase II
Kawiak, A., Piosik, J., Stasiłojć, G., Gwizdek‐Wiśniewska, A., Marczak, Ł., Stobiecki, M., Bigda, J., & Łojkowska, E. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.05.018 · Cited by 89
Consequences of topoisomerase II inhibition in early embryogenesis of Drosophila revealed by in vivo confocal laser scanning microscopy
Buchenau, P., Saumweber, H., & Arndt‐Jovin, D. J. (1993) · Journal of Cell Science · doi:10.1242/jcs.104.4.1175 · Cited by 89
Effects of analogs of the DNA minor groove binder Hoechst 33258 on topoisomerase II and I mediated activities
Beerman, T. A., McHugh, M. M., Sigmund, R. D., Lown, J. W., Rao, K. E., & Bathini, Y. (1992) · Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression · doi:10.1016/0167-4781(92)90098-k · Cited by 87
Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line
Sullivan, D. M., Latham, M. D., Rowe, T., & Ross, W. E. (1989) · Biochemistry · doi:10.1021/bi00439a051 · Cited by 87
Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase I and II activities.
Riou, J., Fossé, P., Nguyen, C.-H., Larsen, A. K., Bissery, M.-C., Grondard, L., Saucier, J.-M., Bisagni, É., & Lavelle, F. (1993) · PubMed · Cited by 86
Pharmacology of mitoxantrone: mode of action and pharmacokinetics
Alberts, D. S., Peng, Y. M., Bowden, G. T., Dalton, W. S., & Mackel, C. (1985) · Investigational New Drugs · doi:10.1007/bf00174156 · Cited by 85
Mitoxantrone affects topoisomerase activities in human breast cancer cells
Crespi, M. D., Ivanier, S. E., Genovese, J. A., & Baldi, A. (1986) · Biochemical and Biophysical Research Communications · doi:10.1016/0006-291x(86)90471-7 · Cited by 85
Precise localization of the alpha-globin gene cluster within one of the 20- to 300-kilobase DNA fragments released by cleavage of chicken chromosomal DNA at topoisomerase II sites in vivo: evidence that the fragments are DNA loops or domains.
Razin, S. V., Petrov, P., & Hancock, R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8515 · Cited by 85
Etoposide (VP-16-213)-induced gene alterations: potential contribution to cell death.
Berger, N. A., Chatterjee, S., Schmotzer, J. A., & Helms, S. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.19.8740 · Cited by 85
Pharmacokinetic Optimisation of Treatment with Oral Etoposide
Toffoli, G., Corona, G., Basso, B., & Boiocchi, M. (2004) · Clinical Pharmacokinetics · doi:10.2165/00003088-200443070-00002 · Cited by 84
Differential induction of Leishmania donovani bi-subunit topoisomerase I-DNA cleavage complex by selected flavones and camptothecin: activity of flavones against camptothecin-resistant topoisomerase I
Das, B. B. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj502 · Cited by 84
Sequence-dependent effect of camptothecin on human topoisomerase I DNA cleavage
Kjeldsen, E., Mollerup, S. K., Thomsen, B., Bonven, B. J., Bolund, L., & Westergaard, O. (1988) · Journal of Molecular Biology · doi:10.1016/0022-2836(88)90462-7 · Cited by 84
DNA topoisomerase II as a target of antineoplastic drug therapy
Zwelling, L. A. (1985) · Cancer and Metastasis Reviews · doi:10.1007/bf00048092 · Cited by 83
Cellular responses to etoposide: cell death despite cell cycle arrest and repair of DNA damage
Schonn, I., Hennesen, J., & Dartsch, D. C. (2009) · APOPTOSIS · doi:10.1007/s10495-009-0440-9 · Cited by 82
A laccase-catalysed one-pot synthesis of aminonaphthoquinones and their anticancer activity
Wellington, K. W., & Kolesnikova, N. I. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.05.028 · Cited by 81
DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs
Shen, L. L., Baranowski, J. L., Fostel, J. M., Montgomery, D., & Lartey, P. A. (1992) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.36.12.2778 · Cited by 82
Characterization of a camptothecin-resistant human DNA topoisomerase I.
Kjeldsen, E., Bonven, B. J., Andoh, T., Ishii, K., Okada, K., Bolund, L., & Westergaard, O. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)69012-x · Cited by 82
DNA topoisomerase-targeting chemotherapeutics: what’s new?
Cuya, S. M., Bjornsti, M., & van Waardenburg, R. C. A. M. (2017) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3334-5 · Cited by 81

Authors: Tewey, K. M., Chen, G. L., Nelson, E. M., & Liu, L. F.
Affiliations: Johns Hopkins University (US)
ORCID: Liu, L F
Venue: Journal of Biological Chemistry
Publisher: Elsevier BV
Published: 1984-07
Volume: 259
Issue: 14
Pages: 9182-9187
ISSN: 0021-9258 (ISSN-L)
DOI: 10.1016/s0021-9258(17)47282-6
OpenAlex: W1514525963
Cited by: 887
References: 39
Citations by year: 2026: 2 · 2025: 6 · 2024: 4 · 2023: 4 · 2022: 6 · 2021: 9 · 2020: 10 · 2019: 16 · 2018: 9 · 2017: 15 · 2016: 19 · 2015: 14 · 2014: 14 · 2013: 16 · 2012: 14
FWCI: 15.02
Type: journal article
Language: en
Open access: hybrid
doi.org
Licence: cc-by
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
creativecommons.org/licenses/by/4.0/ (vor, 13270 d)
Locations: Journal of Biological Chemistry (publishedVersion, cc-by)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
Keywords: topoisomerase II, epipodophyllotoxins, etoposide, doxorubicin, cleavable complex, drug-enzyme interaction, nalidixic acid, DNA gyrase, cytotoxicity mechanism
MeSH terms: Alkaloids, Animals, Antineoplastic Agents, Cattle, DNA, DNA Topoisomerases, Type II, DNA Topoisomerases, Type I, DNA, Viral, Ellipticines, HeLa Cells, Humans, Intercalating Agents, Kinetics, Osmolar Concentration, Plasmids, Protein Binding, Thymus Gland

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks